Before using this supplement, it is recommended to consult with a medical professional regarding individual circumstances and appropriate dosage schedules
(2000), Horm Res 53(Suppl 3), PubMed 10971106 Statistics from preclinical literature AOD-9604 = modified fragment of hGH 177191 + N-terminal Tyr (sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe), molecular weight 1815.1 Da Developed at Metabolic Pharmaceuticals (Australia) based on the work of professor Frank Ng (Monash University) in the 1990s Standard experimental dose in obesity clinical trials: 1 mg/day subcutaneously (Phase 2b, Heffernan et al.) Mechanism: stimulation of 3-adrenergic receptors in adipose tissue, increased lipolysis and fatty acid oxidation without activation of the hGH receptor (no IGF-1 increase) Phase 2b clinical trial (2007, 300 patients): weight reduction ~2.8 kg vs placebo over 12 weeks FDA status: NDI rejection (2014) as a dietary supplement

Research Data Stack Suggestions AOD-9604 + MOTS-c Synergistic activation of AMPK and mitochondrial oxidation for enhanced energy expenditure AOD-9604 + L-Carnitine Amplifies fat transport into mitochondria for improved fatty acid utilization AOD-9604 + Tesamorelin Dual-pathway lipolysis stimulation (GH-releasing + GH fragment synergy) AOD-9604 + Rttrutd / rztd Complementary metabolic pathways for obesity and insulin control research
PMID 18245139
It involves a minimally invasive approach, with the surgeon making small incisions in the abdomen
At this concentration, a 5mg dose is a clean 25 units and a 10mg dose is 50 units